Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerMartin L. Sos, Roman K. Thomas, Roland T. Ullrich et al.|Proceedings of the National Academy of Sciences|2009Cited by 255
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancerSampurna Chatterjee, Roland T. Ullrich|Journal of Clinical Investigation|2013Cited by 193
Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET)Roland T. Ullrich, Alexandra Winkeler|PLoS ONE|2008Cited by 91
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancerJakob Schöttle, Roland T. Ullrich|Oncotarget|2015Cited by 21
EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung CancerCarolin Selenz, Roland T. Ullrich|Cancers|2022Cited by 20